Form 4: Akebia Legal Officer Sells Shares for Tax Obligations

Akebia Therapeutics' SVP, Chief Legal Officer, Carolyn M. Rucci, sold 69,772 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Carolyn M. Rucci, SVP, Chief Legal Officer of Akebia Therapeutics, Inc. (AKBA), sold a total of 69,772 shares of common stock on February 2, 2026.
• The sales were executed at a price of $1.39 per share, totaling approximately $96,982.48.
• These transactions were made automatically by the Issuer to cover tax withholding obligations associated with the vesting and settlement of restricted stock units granted on January 31, 2023, January 31, 2024, and January 31, 2025.
• The sales were conducted under a Rule 10b5-1 trading plan adopted by Ms. Rucci on September 8, 2025.
• Following these transactions, Ms. Rucci beneficially owns 588,378 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sales are for tax purposes related to RSU vesting and were pre-scheduled under a 10b5-1 plan, indicating no discretionary selling based on new information.

Positives

• The sales were pre-scheduled under a Rule 10b5-1 trading plan, indicating a pre-planned, non-discretionary transaction rather than an immediate reaction to market conditions.
• The sales were specifically for tax withholding, which is a common and expected event for executives receiving equity compensation.

Negatives

• The transaction represents a reduction in direct beneficial ownership by a key executive, albeit for tax purposes.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• "This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2025."
• "This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2023."
• "This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2024."
• "This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on January 31, 2025."

Industry Context

StockSavvy.ai notes that executive sales for tax withholding purposes upon RSU vesting are a routine occurrence in the biotechnology and pharmaceutical industry, reflecting standard compensation practices rather than a specific market outlook. Such transactions are common across publicly traded companies where equity compensation is a significant component of executive pay.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans for executive stock sales is a standard corporate governance practice, aligning with SEC guidelines to prevent insider trading. Companies like Pfizer, Moderna, and Johnson & Johnson frequently disclose similar tax-related sales by executives under pre-arranged plans.
• The mechanism of the issuer automatically selling shares to cover tax obligations is a common method for managing RSU vesting, seen across various industries and companies of similar market capitalization to Akebia Therapeutics.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but for a routine tax purpose, unlikely to signal a change in management confidence.
• Employees: No direct impact on employees beyond the reporting person.

Key Dates

Recommendation

The filing details routine insider stock sales by a Chief Legal Officer to cover tax obligations associated with restricted stock unit vesting, executed under a pre-arranged Rule 10b5-1 plan. This is a non-discretionary transaction and does not reflect a change in the executive's confidence in the company's future prospects. As such, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation.

Keywords

Akebia Therapeutics, AKBA, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU, Tax Withholding, Rule 10b5-1, Carolyn M. Rucci, Chief Legal Officer